Recruiting studies: Borderline Resectable Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Phase 2 · 5 location(s) · University Hospital, Bonn · NCT06810609 Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Phase 3 · 1 location(s) · Sahlgrenska University Hospital · NCT06714604 Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05085496 Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal
Phase 2 · 1 location(s) · Chuangzhen Chen · NCT07339488 Stereotactic Magnetic Resonance Guided Radiation Therapy
NA · 2 location(s) · Dana-Farber Cancer Institute · NCT04115254 Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Phase 2 · 4 location(s) · Proton Collaborative Group · NCT02598349 Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Chola
Phase 2 · 1 location(s) · Jinbo Yue · NCT07030140 CEB-01 in Locally Resectable Pancreatic Cancer
Phase 2 · 4 location(s) · CEBIOTEX · NCT06538857 Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
Phase 2 · 1 location(s) · Lei ZHAO · NCT06904014 Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Phase 2 · 1 location(s) · Susan E. Bates · NCT05241249 A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small C
Phase 1 · 4 location(s) · University of Maryland, Baltimore · NCT06800339 Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Ca
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07638436

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.